AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Study to Evaluate the Amount of Drug That Becomes Available in the Blood Circulation When Savolitinib is Administered Alone and in Combination With Itraconazole
- First Posted Date
- 2019-10-10
- Last Posted Date
- 2020-01-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT04121910
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
A Study in Healthy Subjects to Assess the Pharmacokinetics of Savolitinib When Administered Alone and in Combination With Rifampicin
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 40
- Registration Number
- NCT04118842
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate CancerMetastatic Castration-Resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 59
- Registration Number
- NCT04089553
- Locations
- 🇺🇸
Research Site, Nashville, Tennessee, United States
A Study to Assess the Drug Absorption Into the Blood After Administration of 3 Doses of AZD5718
Phase 1
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: Treatment ADrug: Treatment BDrug: Treatment C
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT04087187
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer
Phase 1
Completed
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2019-09-12
- Last Posted Date
- 2022-07-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT04087174
- Locations
- 🇪🇸
Research Site, Barcelona, Spain
Study Comparing Dual Combination of Product (Budesonide and Formoterol) Given Via Two Different Inhalers. To See Which One Results in the Best Effect on Breathing.
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Combination Product: Symbicort TurbuhalerCombination Product: BFF
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 35
- Registration Number
- NCT04078126
- Locations
- 🇩🇪
Research Site, Landsberg, Germany
Durvalumab Long-Term Safety and Efficacy Study
- First Posted Date
- 2019-09-04
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 163
- Registration Number
- NCT04078152
- Locations
- 🇻🇳
Research Site, Hanoi, Vietnam
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers
- First Posted Date
- 2019-09-03
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT04076540
- Locations
- 🇺🇸
Research Site, Austin, Texas, United States
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
Phase 3
Active, not recruiting
- Conditions
- Untreated Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 155
- Registration Number
- NCT04075292
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Post-Authorisation Safety Study of Lesinurad
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT04072471
© Copyright 2025. All Rights Reserved by MedPath